Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Theravance Biopharma, Inc. (TBPH)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/24/2023 |
4
| Farnum Rhonda (SVP, COMM & MEDICAL AFFAIRS) has filed a Form 4 on Theravance Biopharma, Inc.|
Txns:
| Sold 1,807 shares
@ $9.47, valued at
$17.1k
|
|
| 08/22/2023 |
4
| Winningham Rick E (CEO) has filed a Form 4 on Theravance Biopharma, Inc.|
Txns:
| Paid exercise price by delivering 15,804 shares
@ $9.7, valued at
$153.3k
|
|
| 08/22/2023 |
4
| Sawaf Aziz (SVP & CFO) has filed a Form 4 on Theravance Biopharma, Inc.|
Txns:
| Paid exercise price by delivering 7,114 shares
@ $9.7, valued at
$69k
|
|
| 08/22/2023 |
4
| Grimaud Brett A. (SVP, GEN COUNSEL AND SECRETARY) has filed a Form 4 on Theravance Biopharma, Inc.|
Txns:
| Paid exercise price by delivering 8,912 shares
@ $9.7, valued at
$86.4k
|
|
| 08/22/2023 |
4
| GRAHAM RICHARD A (SVP, RESEARCH & DEVELOPMENT) has filed a Form 4 on Theravance Biopharma, Inc.|
Txns:
| Paid exercise price by delivering 10,461 shares
@ $9.7, valued at
$101.5k
|
|
| 08/22/2023 |
4
| Farnum Rhonda (SVP, COMM & MEDICAL AFFAIRS) has filed a Form 4 on Theravance Biopharma, Inc.|
Txns:
| Paid exercise price by delivering 10,460 shares
@ $9.7, valued at
$101.5k
|
|
| 08/15/2023 |
4
| GRAHAM RICHARD A (SVP, RESEARCH & DEVELOPMENT) has filed a Form 4 on Theravance Biopharma, Inc.|
Txns:
| Sold 2,322 shares
@ $9.99, valued at
$23.2k
|
|
| 08/14/2023 |
SC 13D/A
| Weiss Asset Management LP reports a 14.1% stake in Theravance Biopharma, Inc. |
| 08/11/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/07/2023 |
8-K
| Quarterly results |
| 07/18/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/14/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/10/2023 |
SC 13G/A
| Baupost Group reports a 12.8% stake in Theravance Biopharma, Inc. |
| 06/16/2023 |
4
| GRAHAM RICHARD A (SVP, RESEARCH & DEVELOPMENT) has filed a Form 4 on Theravance Biopharma, Inc.|
Txns:
| Sold 2,322 shares
@ $10.69, valued at
$24.8k
|
|
| 06/12/2023 |
4
| Farnum Rhonda (SVP, COMM & MEDICAL AFFAIRS) has filed a Form 4 on Theravance Biopharma, Inc.|
Txns:
| Sold 1,790 shares
@ $11.13, valued at
$19.9k
|
|
| 06/09/2023 |
8-K
| Termination of a Material Definitive Agreement Interactive Data |
| 06/08/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/23/2023 |
4
| Winningham Rick E (CEO) has filed a Form 4 on Theravance Biopharma, Inc.|
Txns:
| Paid exercise price by delivering 15,804 shares
@ $11.21, valued at
$177.2k
|
|
| 05/23/2023 |
4
| Sawaf Aziz (SVP & CFO) has filed a Form 4 on Theravance Biopharma, Inc.|
Txns:
| Paid exercise price by delivering 8,744 shares
@ $11.21, valued at
$98k
|
|
| 05/23/2023 |
4
| Grimaud Brett A. (SVP, GEN COUNSEL AND SECRETARY) has filed a Form 4 on Theravance Biopharma, Inc.|
Txns:
| Paid exercise price by delivering 11,469 shares
@ $11.21, valued at
$128.6k
|
|
| 05/23/2023 |
4
| GRAHAM RICHARD A (SVP, RESEARCH & DEVELOPMENT) has filed a Form 4 on Theravance Biopharma, Inc.|
Txns:
| Paid exercise price by delivering 10,460 shares
@ $11.21, valued at
$117.3k
|
|
| 05/23/2023 |
4
| Farnum Rhonda (SVP, COMM & MEDICAL AFFAIRS) has filed a Form 4 on Theravance Biopharma, Inc.|
Txns:
| Paid exercise price by delivering 5,567 shares
@ $11.21, valued at
$62.4k
|
|
| 05/17/2023 |
4
| GRAHAM RICHARD A (SVP, RESEARCH & DEVELOPMENT) has filed a Form 4 on Theravance Biopharma, Inc.|
Txns:
| Sold 2,322 shares
@ $11.26, valued at
$26.1k
|
|
| 05/15/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/08/2023 |
8-K
| Quarterly results |
| 05/04/2023 |
4
| PAKIANATHAN DEEPIKA (Director) has filed a Form 4 on Theravance Biopharma, Inc.|
Txns:
| Granted 9,132 shares
@ $0
Granted 22,044 options to buy
@ $10.95, valued at
$241.4k
|
|
| 05/04/2023 |
4
| O'Connor Donal (Director) has filed a Form 4 on Theravance Biopharma, Inc.|
Txns:
| Granted 9,132 shares
@ $0
Granted 22,044 options to buy
@ $10.95, valued at
$241.4k
|
|
| 05/04/2023 |
4
| MITCHELL DEAN J (Director) has filed a Form 4 on Theravance Biopharma, Inc.|
Txns:
| Granted 9,132 shares
@ $0
Granted 22,044 options to buy
@ $10.95, valued at
$241.4k
|
|
| 05/04/2023 |
4
| MALKIEL BURTON G (Director) has filed a Form 4 on Theravance Biopharma, Inc.|
Txns:
| Granted 9,132 shares
@ $0
Granted 22,044 options to buy
@ $10.95, valued at
$241.4k
|
|
| 05/04/2023 |
4
| GRAY SUSANNAH (Director) has filed a Form 4 on Theravance Biopharma, Inc.|
Txns:
| Granted 9,132 shares
@ $0
Granted 22,044 options to buy
@ $10.95, valued at
$241.4k
|
|
| 05/04/2023 |
4
| BROSHY ERAN (Director) has filed a Form 4 on Theravance Biopharma, Inc.|
Txns:
| Granted 9,132 shares
@ $0
Granted 22,044 options to buy
@ $10.95, valued at
$241.4k
|
|
| 05/04/2023 |
4
| Smaldone Alsup Laurie (Director) has filed a Form 4 on Theravance Biopharma, Inc.|
Txns:
| Granted 9,132 shares
@ $0
Granted 22,044 options to buy
@ $10.95, valued at
$241.4k
|
|
|
|
|